Stevenage, UK and Madrid, Spain, 1 July 2018–Today is a great day for Aglaris. Due to the preparation to take our company to the next stage, there has been a change of relevance for all. Through this e-mail, it is an honor for us to introduce to you the new CEO of the company, Steven Docksey, who will join the management team of Aglaris as of today, July 1. Steven will be working part-time and will also join the Board of Directors.
Aglaris Appoints Steven Docksey as CEO
It is a privilege for us to have Steve in Aglaris, given his career path within the world of Bioprocessing. Steve has held senior management positions with world leading companies including: GE Healthcare Life Scienses – Chief Marketing Officer, Millipore Corporation – VP Global Marketing, Millipore Europe – Managing Director, Stedim Biosystems – VP Business Operations. Steve started his career in technology as a research microbiologist and has over 30 years experience in life sciences and healthcare. He has attended senior management programmes at INSEAD business school in Fontainebleau.
Steve will help us take Aglaris one step further. This movement does not imply any changes in the strategy that we have maintained during the last years as we are very satisfied with our trajectory and we want to maintain it.
Dr David Horna
Dr Miquel Costa
NOTES TO EDITOR
About Aglaris Ltd
Aglaris Limited (Aglaris) is developing innovative, automated cell culture platform technologies. Set up in 2014, Aglaris aims to solve the bottleneck in cell and tissue manufacturing, currently inhibiting the wider application of cell-based therapies within regenerative medicine.
Aglaris has a clear aspiration to provide an enabling technology platform to make cell therapy a reality. Novel platforms and stem cell approaches are emerging as potentially promising therapies across a wide range of disease areas. This fast-growing global stem cell market is expected to increase threefold and reach £135 billion by 2020. To meet the needs of cell therapies, cell production needs to be more affordable and technically competitive. Aglaris has developed the Facer 1.0 prototype (integrating the Aglaris technology in an automated bioreactor) and a number of ancillary technologies (e.g., microparticles, filtration system, sensor array etc.) which are currently under validation at Aglaris’ headquarters at the Stevenage Bioscience Catalyst (UK) and its laboratory premises at Parque Tecnológico de Madrid (Spain).
The experienced management team and board bring a proven track record of clinical and scientific credentials in founding, developing and commercialisation of technologies. Investments in Aglaris to date include grants and venture funding from renowned public and private institutions. For further information, please visit www.aglaris.co.uk.